A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Diseases and Conditions Researched

Idiopathic Pulmonary Fibrosis

What is the purpose of this trial?

The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis.


Participation Guidelines

Age: 45 Years - 85 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Gilead Sciences
Dates:
Last Updated:
Study HIC#: 1304011925